PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy

EJNMMI Research

Table 3 ⁶⁸Ga-PSMA-11 PET findings

Characteristic	Patients
miTNM classification, no. (%), n = 186
miT status
2u	73 (39.2%)
2m	52 (28%)
3a	27 (14.5%)
3b	24 (12.9%)
4	10 (5.4%)
miN status
0	168 (90.3%)
1	7 (3.8%)
2	11 (5.9%)
miM status
0	179 (96.2%)
1a	3 (1.6%)
1b	4 (2.2%)
PSMA-PET findings of prostatic lesions, median (IQR), n = 183^a
SUV_max	10.6 (6.4–18.9)
SUV_mean	6.2 (3.2–11.0)
TV	3.9 (1.7–10.5)
TL	24.7 (15.9–44.4)

IQR interquartile range, PET positron emission tomography, PSMA prostate-specific membrane antigen, SUV standardized uptake value, TL total lesion, TV tumor volume
^aThree patients had PSMA negative prostate cancer. miTNM of these patients were classified based on MRI images